KRAS and neoplasm: No significant association existed between EZH2 expression and the clinical or pathological characteristics such as gender, age, tumor size, year of diagnosis, tumor location, tumor differentiation and disease stage; BRAF, KRAS, and PIK3CA mutations; and the MSI (microsatellite instability) and CpG island methylator phenotype (CIMP) status (Table 1).